Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells

Table 1 Analysis of growth factor concentration by ELISA in different PL and PI-PL preparations

PL preparations	PDGF-AB* (pg/ml)	VEGF^§ (pg/ml)	bFGF° (pg/ml)	TGF-beta1^#(pg/ml)
PL1	42,778 ± 10,206	15,666 ± 1,257	94.6 ± 6.11	88,590 ± 3,169
PL2	32,071 ± 2,525	11,239 ± 673	111.6 ± 1.40	72,694 ± 3,245
PL3	26,272 ± 1,105	10,571 ± 514	91.3 ± 3.21	90,637 ± 533
PI-PL1	25,586 ± 1,281	11,276 ± 1,108	110 ± 10	63,512 ± 1,500
PI-PL2	35,140 ± 1,624	10,119 ± 827	118 ± 2.88	70,626 ± 2,013
PI-PL3	41,299 ± 2.041	11,187 ± 757	109 ± 3.60	90,188 ± 1.051

PL platelet lysate, PI-PL pathogen inactivated platelet lysate, PDGF-AB platelet derived growth factor AB, VEGF vascular endothelial growth factor, bFGF basic fibroblast growth factor, TGF-beta1 transforming growth factor beta1; means ± standard deviations are shown of a triplicate assay performed to detect each growth factor concentration. *p = 0.937, ^§p = 0.119, °p = 0.009 (in favour of PI-PL), ^#p = 0.082 at unpaired two-tailed Student’s T test between concentrations observed in control PL and PI-PL lots.

ISSN: 1479-5876